Imugene (IUGNF)
OTHER OTC:IUGNF
Want to see IUGNF full AI Analyst Report?
IUGNF Stock Chart & Stats
$0.18
>-$0.01(-3.57%)
At close: 4:00 PM EST
$0.18
>-$0.01(-3.57%)
Day’s Range― - ―
52-Week Range$0.03 - $0.65
Previous CloseN/A
Volume3.00K
Average Volume (3M)16.95K
Market Cap
$38.60M
Enterprise Value$44.95M
Total Cash (Recent Filing)$14.14M
Total Debt (Recent Filing)$5.02M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Sep 02, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding415,835,050
10 Day Avg. Volume11,247
30 Day Avg. Volume16,948
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue14.32
Enterprise Value/Gross Profit16.12
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
$0.18Price Target Upside-0.89% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$3.62M
Bulls Say, Bears Say
Bulls Say
Focused Immuno-oncology PipelineA concentrated R&D focus on multiple immuno-oncology modalities (oncolytic viruses, B-cell activators, CAR-T/engagers) strengthens the long-term clinical and partnering optionality. Multiple distinct platforms increase chances of a value-inflecting asset and make the business model attractive to collaborators.
Conservative Balance Sheet LeverageLow debt-to-equity (0.24) provides financial flexibility and reduces insolvency risk during lengthy clinical development cycles. With limited leverage, management can prioritize R&D and partnerships without near-term debt servicing constraints, preserving strategic optionality over months to years.
High Reported Gross Profit MarginA 100% gross margin suggests that any future commercialized products or licensing revenues could convert strongly to gross profit, improving scalability. For a clinical-stage biotech, high product-level margins support attractive economics for partners and licensees if clinical success leads to revenue.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow indicates ongoing cash burn from R&D and operations, requiring continuous external financing until commercialization or partnering. Over 2-6 months this constrains runway, increases dilution risk, and forces prioritization of programs.
Severe Revenue Decline And LossesA dramatic revenue contraction and sustained negative margins reflect limited commercial revenue and unprofitable operations. Structurally, this reduces internal funding capacity, undermines operating leverage, and means progress depends on clinical milestones or external deals to reverse fundamentals.
Dependence On Investor FundingReliance on equity raises and occasional licensing means the firm is exposed to capital markets for continuation of programs. This creates long-term dilution risk and vulnerability to funding market conditions, which can delay programs or force less favorable partner deals when market access tightens.
Imugene News
IUGNF FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest stock price was $0.03 and its highest was $0.65 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is $38.60M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Sep 02, 2026 which is in 100 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -$0.093 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.15.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.03.
How many shares outstanding does Imugene have?
Imugene has 415,835,050 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -$0.093 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in IUGNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.18 (-0.89% Downside)
$0.18 (-0.89% Downside)
Blogger Sentiment
Bullish
IUGNF Sentiment 61%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $63.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.97%
12-Months-Change
Fundamentals
Return on Equity
-134.65%
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
IUGNF Stock 12 Month Forecast
Average Price Target
$0.18
▼(-0.89% Downside)
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Ownership Overview
3.95% Insiders
0.88% Mutual Funds
― Other Institutional Investors
95.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---